June 13, 2024 10:34 AM EDT
News Briefing

Avid­i­ty’s $300M of­fer­ing; Rap­port rais­es $174M

Lei Lei Wu

News Reporter

Plus, news about Replim­mune, No­vo Nordisk and Bios­plice:

Avid­i­ty Bio­sciences is look­ing for $300M in stock sale: The RNA com­pa­ny is plan­ning a $300 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lex­i­con ends com­mer­cial work to fo­cus on R&D

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times